Deltec Asset Management’s NRX Pharmaceuticals NRXP Stock Holding History

Deltec Asset Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-7,500	Closed	-$732K	–	194
2018 Q1	$732K	Hold	7,500	–	–	0.15%	117
2017 Q4	$728K	Buy	+7,500	New	+$725K	0.15%	104

Other funds holding NRXP

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Bank of Montreal

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Deltec Asset Management's NRXP Position: Q2 2018 in Review

Deltec Asset Management sold out of NRX Pharmaceuticals (NRXP) in Q2 2018, closing a stake of 7,500 shares — an estimated $732K sold.

Deltec Asset Management first reported a position in NRXP in Q4 2017 and held it in 2 quarters. The position peaked at $732K in Q1 2018. 19 funds tracked by Wall St. Rank hold NRXP as of Q2 2018.

Deltec Asset Management reported no remaining NRX Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Deltec Asset Management sold 7,500 NRX Pharmaceuticals shares in Q2 2018, an estimated $732K.
Deltec Asset Management first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 2 quarters.
Deltec Asset Management's NRX Pharmaceuticals position peaked at $732K in Q1 2018.
19 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2018.

Based on Deltec Asset Management's 13F filing for Q2 2018, filed 7 Aug 2018.